Jpmorgan Chase & CO Seres Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 39,443 shares of MCRB stock, worth $28,398. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,443

Previous 66,016 40.25%

Holding current value

$28,398

Previous $92,000 67.39%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.75 - $1.56 $19,929 - $41,453	-26,573 Reduced 40.25%	39,443 $30,000
Q4 2023 Feb 12, 2024	SELL	$0.93 - $2.15 $72,205 - $166,926	-77,640 Reduced 54.05%	66,016 $92,000
Q3 2023 Nov 14, 2023	BUY	$2.33 - $5.07 $8,520 - $18,540	3,657 Added 2.61%	143,656 $341,000
Q2 2023 Aug 11, 2023	SELL	$4.67 - $6.55 $2.26 Million - $3.17 Million	-484,022 Reduced 77.57%	139,999 $670,000
Q1 2023 May 18, 2023	BUY	$4.95 - $6.09 $490,693 - $603,701	99,130 Added 18.89%	624,021 $3.54 Million

Q1 2023 May 11, 2023	SELL	$4.95 - $6.09 $433,907 - $533,837	-87,658 Reduced 14.31%	524,891 $2.98 Million
Q4 2022 Feb 13, 2023	SELL	$5.09 - $9.05 $497,924 - $885,307	-97,824 Reduced 13.77%	612,549 $3.43 Million
Q3 2022 Nov 14, 2022	SELL	$3.5 - $7.2 $246,648 - $507,391	-70,471 Reduced 9.02%	710,373 $4.56 Million
Q2 2022 Aug 11, 2022	BUY	$2.7 - $7.62 $1.72 Million - $4.87 Million	638,779 Added 449.64%	780,844 $2.68 Million
Q1 2022 May 11, 2022	BUY	$6.3 - $8.84 $669,066 - $938,816	106,201 Added 296.12%	142,065 $1.01 Million
Q4 2021 Feb 10, 2022	SELL	$6.02 - $11.43 $3.43 Million - $6.51 Million	-569,573 Reduced 94.08%	35,864 $300,000
Q3 2021 Nov 12, 2021	BUY	$5.46 - $22.6 $3.31 Million - $13.7 Million	605,437 New	605,437 $4.21 Million

Others Institutions Holding MCRB

# of Institutions

100

Shares Held

62.7M

Call Options Held

36.9K

Put Options Held

476K

View Full List

About Seres Therapeutics, Inc.

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

More about MCRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Seres Therapeutics, Inc. Transaction History